Roger Susi Sells 2,500 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the stock in a transaction dated Tuesday, March 24th. The stock was sold at an average price of $100.28, for a total transaction of $250,700.00. Following the completion of the sale, the chief executive officer directly owned 2,232,500 shares in the company, valued at approximately $223,875,100. This trade represents a 0.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

iRadimed Stock Down 3.0%

iRadimed stock opened at $98.74 on Friday. iRadimed Corporation has a 52-week low of $47.48 and a 52-week high of $107.90. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of 56.42 and a beta of 1.12. The firm has a 50-day moving average price of $100.46 and a two-hundred day moving average price of $90.28.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.05. The company had revenue of $22.69 million for the quarter, compared to analysts’ expectations of $21.60 million. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Research analysts expect that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were given a dividend of $0.20 per share. This is a boost from iRadimed’s previous quarterly dividend of $0.17. The ex-dividend date was Monday, February 23rd. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. iRadimed’s payout ratio is presently 45.71%.

Hedge Funds Weigh In On iRadimed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IRMD. CWM LLC raised its stake in shares of iRadimed by 19.5% in the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after buying an additional 107 shares in the last quarter. Johnson Investment Counsel Inc. boosted its stake in iRadimed by 0.7% during the third quarter. Johnson Investment Counsel Inc. now owns 25,842 shares of the medical equipment provider’s stock valued at $1,839,000 after buying an additional 187 shares in the last quarter. Summit Global Investments boosted its stake in iRadimed by 2.7% during the third quarter. Summit Global Investments now owns 7,139 shares of the medical equipment provider’s stock valued at $508,000 after buying an additional 188 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after acquiring an additional 234 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in iRadimed by 4.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock worth $567,000 after acquiring an additional 267 shares in the last quarter. 92.34% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

IRMD has been the topic of a number of research analyst reports. Roth Mkm reissued a “buy” rating and set a $120.00 price target on shares of iRadimed in a report on Tuesday, February 10th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Finally, Lake Street Capital reissued a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, iRadimed currently has a consensus rating of “Moderate Buy” and a consensus target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.